Article Versions Notes

Hurwitz SJ, De R, LeCher JC, Downs-Bowen JA, Goh SL, Zandi K, McBrayer T, Amblard F, Patel D, Kohler JJ, et al. Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections. Viruses. 2024; 16(4):651. https://doi.org/10.3390/v16040651

Hurwitz, Selwyn J., Ramyani De, Julia C. LeCher, Jessica A. Downs-Bowen, Shu Ling Goh, Keivan Zandi, Tamara McBrayer, Franck Amblard, Dharmeshkumar Patel, James J. Kohler, and et al. 2024. "Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections" Viruses 16, no. 4: 651. https://doi.org/10.3390/v16040651

Hurwitz, S. J., De, R., LeCher, J. C., Downs-Bowen, J. A., Goh, S. L., Zandi, K., McBrayer, T., Amblard, F., Patel, D., Kohler, J. J., Bhasin, M., Dobosh, B. S., Sukhatme, V., Tirouvanziam, R. M., & Schinazi, R. F. (2024). Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections. Viruses, 16(4), 651. https://doi.org/10.3390/v16040651